The deal is expected to close by August 31, 2025, subject to regulatory approvals and customary closing conditions. "This strategic acquisition aligns perfectly with our global medical cannabis growth strategy and brings complementary product offerings to our portfolio," said Miguel Martin, Chief Executive Officer of Aurora Cannabis, in the filing. MedLeaf Therapeutics, known for its high-potency medical formulations and clinical research programs, reported annual revenue of $78 million for its fiscal year ended December 2024. The company operates two GMP-certified production facilities with a combined annual capacity of 35,000 kilograms. Aurora expects the acquisition to be accretive to earnings within the first full year of operations and projects annual cost synergies of approximately $15 million through operational efficiencies and supply chain optimization. The company stated that MedLeaf's executive team will join Aurora to ensure operational continuity and facilitate integration of the businesses.